Atreca (USA: $BCEL) Ready For Biotech Boom 2022! 🧬

Atreca , Inc. , a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor , Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca , Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.